Based upon this evaluation, our chief executive officer and chief financial officer have concluded that our Disclosure Controls and Procedures were not effective as of June 30, 2026, due to material weaknesses in our internal control over financial reporting, which are described below.

filing / Aug 17, 2026 / receipt

for approximately 7,843 square feet of office space in Florham Park, New Jersey. The sublease incorporates the applicable terms

filing / Aug 17, 2026 / receipt

Based upon this evaluation, our chief executive officer and chief financial officer have concluded that our Disclosure Controls and Procedures were not effective as of June 30, 2026, due to material weaknesses in our internal control over financial reporting, which are described below.

filing / Aug 17, 2026 / receipt

for approximately 7,843 square feet of office space in Florham Park, New Jersey. The sublease incorporates the applicable terms

filing / Aug 17, 2026 / receipt

Acquired a blue-chip roster of talent across multiple functional areas and led by a renowned foot & ankle surgeon to anchor the corporate mission.

ir_statement / Sep 17, 2026 / receipt

Established the BioNx Surgical division as the engine behind NexGel’s strategic vision, delivering a scalable, high-touch commercialization engine.

ir_statement / Sep 17, 2026 / receipt

Intentionally expanding product lineup around innovative technologies and solutions to improve all parts of the procedural experience, while ensuring the practitioner can deliver procedural excellence

ir_statement / Sep 17, 2026 / receipt

Q3 2025 Gross Profit: $1.24 million & profit margin of 42.4% compared to $1.16 million and 39.2% in Q3 2024.

ir_statement / Sep 16, 2026 / receipt

Revenue guidance of $12 to $12.5 million for 2025 and expect to narrow even further Adjusted EBITDA breakeven for the year.

ir_statement / Sep 16, 2026 / receipt

STADA agreed to provide $1 million in non-dilutive capital to expand the partnership and support new product launches in Q4 2025 and early 2026, including digestive enzyme products for new indications

ir_statement / Sep 16, 2026 / receipt

STADA, a global leader in consumer healthcare, generics, and specialty pharmaceuticals with sales in ~120 countries, is using this partnership to establish a path into the North American market.

ir_statement / Sep 16, 2026 / receipt

Expects revenues to increase sequentially and Q4 will be a record quarter for the company.

ir_statement / Sep 16, 2026 / receipt